NOVAVAX ($NVAX) Releases Q3 2026 Earnings
NOVAVAX ($NVAX) reported Q3 2026 earnings of -$0.19 per share, beating estimates by $0.15. Revenue was $68.3M, exceeding expectations by $16.9M. Institutional investors showed mixed activity, with some increasing and others decreasing their positions.
How this was made

The 30-second read
Why it matters
Earnings beat provides fresh data that could move the stock.
Market read
The earnings surprise offers a short‑term trading edge for NVAX.
What to watch
Potential upcoming regulatory or clinical trial milestones not discussed.
Background
Novavax is a vaccine developer; earnings releases are closely watched for pipeline progress.
Ticker impact
Novavax reported Q3 2026 earnings beating EPS and revenue estimates, providing fresh financial data.
likely upward pressure as the market prices in the earnings beat
The beat on both EPS (-$0.19 vs -$0.34) and revenue ($68.3M vs $51.4M) is material for a micro‑cap biotech and may trigger buying.
Market effects
Positive earnings may lift other small‑cap biotech stocks.
U.S. biotech sector could see modest gains.
Limited to investors tracking biotech earnings.
Counterpoint
The beat may be modest relative to cash burn; investors could stay cautious.
Key entities
- companyNovavax
Vaccine developer reporting Q3 2026 earnings.




